Novel target (IL23-i; Guselkumab) in treating TNF-IR #psoriaticarthritis. Dr Coates presented results from Phase III COSMOS. 44.4% of GUS-treated vs 19.8% Placebo-tx achieved ACR20 response at Wk24 (p<0.001). Well tolerated and No major safety #EULAR2021 #OP0230 @RheumNow https://t.co/EuGaacSuxF

Does Guselkumab (IL23-i) modulate gene expression in #PsA? Dr Siebert analysed samples from DISCOVER RCTs & reported normalisation of⬆️regulated genes (e.g. Neutrophil,monocyte) and ⬇️regulated (B-,T- and NK cells) signatures by GUS post-therapy #EULAR2021 #POS0195 @RheumNow https://t.co/2qtpxrrwkF

⭐️All cancer excluding NMSC - 0.9HR TNFi vs cDMARD ⭐️Squamous cell CA - 1.2HR of TNFi vs cDMARD ⭐️No overall increase in all CA: RTX, TOCI ⭐️Abatacept 1.21HR for all cancer, mainly NMSC ⭐️needs more data on JAKs, IL-17, IL-23 Abs#6916 #EULAR2021 @RheumNow

GUS causes ⬇️ in serum collagen C1M (marker of joint response), C3M, C4M, C6M. Pts achieving ACR20 at week 24 had greater C1M reduction than non-responder. Abstract #POS1036 #EULAR2021 @RheumNow https://t.co/4JqbaMexuR https://t.co/gXltKn6qIc

• http://ow.ly/D1V050F2D5E

In biologic-naïve PsA pts - 2 yr data, GUS improved skin & joint symptoms, physical function, & radiographic progression. Safety comparable to 6mo/1yr data, similar between Q4W & Q8W dosing, & consistent w/ PsO trials. Poster #POS1027 #EULAR2021 @RheumNow https://t.co/nlcjOX7cBq https://t.co/NWqDTwfb4u

• https://ard.bmj.com/content/80/Suppl_1/783

From bedside to bench–unexpected results of clinical studies that changed our understanding of the disease #EULAR2021. “SpA” talk by Prof. Désirée van der Heijde. Inhibition of TNF, IL-17, IL-23, IL-6, IL-1, co-stimulation and B cell depletion in immunology perspective 👏 /TK https://t.co/JFr3VC8sXY

Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24. #psoriaticarthritis https://t.co/S3xnFSQDaJ

• Improved Psoriatic Arthritis Outcomes in Phase 3b Guselkinumab Trial

Guselkumab (IL-23i) 52 week extension study in PsA pts from DISCOVER 1 and 2 ⭐️sustained DAPSA LDA/remission ⭐️sustained PASDAS LDA/vLDA ⭐️sustained MDA POS1024 #EULAR2021 @RheumNow